Previous close | 65.20 |
Open | 65.32 |
Bid | 65.47 x 200 |
Ask | 65.51 x 200 |
Day's range | 64.97 - 65.89 |
52-week range | 64.63 - 87.87 |
Volume | |
Avg. volume | 7,425,481 |
Market cap | 81.689B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 181.97 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (4.70%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | N/A |
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.